Lisa Slade Martin
Psychologist in Wilmington, DE

License number
Delaware B1-0000699
Issued Date
Jan 6, 2005
Expiration Date
Jul 31, 2017
Category
Psychology
Type
Psychologist
Address
Address 2
Wilmington, DE 19802

Professional information

See more information about Lisa Slade Martin at trustoria.com
Lisa Martin Photo 1
Project Manager At Astrazeneca

Project Manager At Astrazeneca

Position:
Project Manager at AstraZeneca Pharmaceuticals
Location:
Wilmington, Delaware
Industry:
Pharmaceuticals
Work:
AstraZeneca Pharmaceuticals since Jan 2011 - Project Manager AstraZeneca Pharmaceuticals Jul 2006 - Jan 2011 - Associate Director, Early Development AstraZeneca Pharmaceuticals 2001 - 2006 - Associate Director, Analytical Development AstraZeneca Pharmaceuticals 1999 - 2001 - Manager, Analytical Development AstraZeneca Pharmaceuticals 1998 - 1999 - Project Manager AstraZeneca Pharmaceuticals 1997 - 1998 - Team Leader AstraZeneca Pharmaceuticals 1996 - 1997 - Manager, Product & Analytical Dev't AstraZeneca Pharmaceuticals 1993 - 1996 - Group Leader AstraZeneca Pharmaceuticals 1990 - 1993 - Analytical Research Chemist Eastman Chemical Company 1988 - 1990 - Research Chemist
Education:
Texas A&M University 1983 - 1988
PhD, Analytical Chemistry
Thiel College 1979 - 1983
BA, Chemistry


Lisa S Martin Photo 2
Dr. Lisa S Martin, Wilmington DE - PHD

Dr. Lisa S Martin, Wilmington DE - PHD

Specialties:
Clinical Psychology
Address:
Partners In Mental Health
1601 Concord Pike SUITE 100, Wilmington 19803
(302) 573-5112 (Phone)
Languages:
English


Lisa Martin Photo 3
Lisa Martin - Wilmington, DE

Lisa Martin - Wilmington, DE

Work:
NEWS JOURNAL
Production/Warehouse Associate
DOVER POST - Dover, DE
Production Associate
CLIENTLOGIC - Dover, DE
Mailroom associate
Education:
DELAWARE TECHNICAL COMMUNITY COLLEGE
Certificate in data entry


Lisa Slade Martin Photo 4
Lisa Slade Martin, Wilmington DE

Lisa Slade Martin, Wilmington DE

Specialties:
Psychologist
Address:
1601 Concord Pike, Wilmington, DE 19803


Lisa Martin Photo 5
Extended Release Compositions And Methods For Their Manufacture

Extended Release Compositions And Methods For Their Manufacture

US Patent:
2008028, Nov 20, 2008
Filed:
Nov 14, 2007
Appl. No.:
11/939585
Inventors:
Daniel Brown - Wilmington DE, US
Donna Caster - Wilmington DE, US
Brian Clark - Macclesfield, GB
Sandra Hopkins - Wilmington DE, US
Jennifer Llewelyn - Wilmington DE, US
Elizabeth Meehan - Macclesfield, GB
Lisa Martin - Wilmington DE, US
Robert Timko - Wilmington DE, US
Husheng Yang - Wilmington DE, US
Assignee:
ASTRAZENECA AB - Sodertalje
International Classification:
A61K 31/554, A61P 25/18
US Classification:
51421113
Abstract:
Extended release formulations of quetiapine and its pharmaceutically salts, and methods for manufacture of the formulations, may include the use of polymers selected for their physical and chemical characteristics. The formulations may include polymers selected to cause solid dosage forms of the formulations to conform to preselected quetiapine release criteria. The formulations may include non-polymer materials that may affect quetiapine release.


Lisa Martin Photo 6
Extended Release Formulations Comprising Quetiapine And Methods For Their Manufacture

Extended Release Formulations Comprising Quetiapine And Methods For Their Manufacture

US Patent:
2011031, Dec 29, 2011
Filed:
Nov 16, 2007
Appl. No.:
12/599861
Inventors:
Daniel Brown - Wilmington DE, US
Donna Caster - Wilmington DE, US
Brian Clark - Cheshire, GB
Sandra Hopkins - Wilmington DE, US
Jennifer Llewelyn - Wilmington DE, US
Lisa Martin - Wilmington DE, US
Elizabeth Meehan - Cheshire, GB
Robert Timko - Wilmington DE, US
Husheng Yang - Wilmington DE, US
Assignee:
ASTRAZENECA AB - Sodertalje
International Classification:
A61K 31/554, A61P 25/18
US Classification:
51421113
Abstract:
The present invention relates to extended release formulations of quetiapine and its pharmaceutically acceptable salts. The formulations comprise polymers, preferably hydroxypropyl methylcellulose of different viscosities, selected to cause the formulations to conform to preselected quetiapine release profiles. A process for the manufacture of said formulations is also disclosed.